India Pharma Outlook Team | Tuesday, 21 April 2026
India’s CDSCO prior intimation mechanism is now live, marking a shift in how drug makers begin early-stage manufacturing for research.
The Central Drugs Standard Control Organisation has rolled out the system from April 21, 2026, replacing the older requirement of securing a test license before producing small batches of new or investigational drugs.
Under the updated New Drugs and Clinical Trials Rules 2019, pharmaceutical companies can start manufacturing limited quantities for testing and analysis by simply submitting an online intimation.
Once acknowledged by the Central Licensing Authority, work can begin without waiting for formal approval. This trust-based system is expected to cut delays that previously slowed early research.
Also Read: The Future of MedTech in India: Meeting Tier-2 and Tier-3 Needs
The reform, first notified on January 17, 2026, aims to remove regulatory friction and support faster innovation. Officials confirmed the rollout through an order issued on April 20, 2026, highlighting its role in improving India’s clinical research environment and ease of doing business.
The CDSCO prior intimation mechanism is expected to save up to 90 days in the drug development cycle. Earlier, companies had to wait for a test license before producing even small quantities for examination, a process that often held back progress from discovery to preclinical stages.
However, the relaxation does not apply across the board. High-risk drug categories such as cytotoxic drugs, sex hormones, beta-lactam antibiotics, biologics with live microorganisms, and narcotic or psychotropic substances will still need prior regulatory clearance.
The move also strengthens India’s push toward digital governance. Applications and approvals are handled through platforms like the National Single Window System, improving transparency and tracking. With fewer bottlenecks and faster approvals, the reform is expected to boost efficiency across India’s pharmaceutical sector.
.jpg)
.jpg)
